Erie, PANCT07419334Now EnrollingIRB Ready

Stargardt Disease Clinical Trial in Erie, PA

Access cutting-edge stargardt disease treatment through this clinical trial at a research site in Erie. Study-provided care at no cost to qualified participants.

Sponsored by Alkeus Pharmaceuticals, Inc.

Quick Self-Assessment

See if you qualify for this Erie location

Preparing your pre-screening questions…

Expert Care in Erie

Access stargardt disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related stargardt disease treatment provided free

Apply for This Erie Location

Check if you qualify for this stargardt disease clinical trial in Erie, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Erie

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Erie site if eligible
  4. 4Begin participation

About This Stargardt Disease Study in Erie

This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)

Sponsor: Alkeus Pharmaceuticals, Inc.

Who Can Participate

Inclusion Criteria

Male or female, 8 to 45 years of age (inclusive) on the day of screening.
Female participants of childbearing potential, as well as fertile male participants with female partners of childbearing potential, must be willing to comply with the protocol-defined methods of contraception from the time of consent until 90 days and 30 days, respectively, after the last dose of IMP.
Have a clinical diagnosis of typical autosomal recessive STGD macular dystrophy
Have provided a genetic report by any regional accredited organization that provides certified testing indicating the presence of disease-causing mutation.
Have signed and dated the informed consent forms (ICFs; or assent as appropriate) to participate.

Exclusion Criteria

Has taken disallowed items (supplements containing vitamin A or beta-carotene, liver-based products, or prescription oral retinoid medications) within 30 days of randomization.
Is lactating, pregnant, or has a positive serum or urine pregnancy test at screening or at randomization, or is planning to become pregnant during the course of study. A male participant who wishes to father a child during the course of the study.
Has ever participated in any gene therapy, cell therapy, or device study to treat STGD, unless documented confirmation of participation in the placebo arm with no surgery is provided. Has participated in a drug study to treat STGD within the past 6 months.
Has participated in any drug study to treat any other condition within 5 half-lives of the investigational drug prior to screening, unless documented confirmation of participation in the placebo arm is provided. Has participated in an investigational device study within 30 days prior to screening or longer if, in the Investigator's judgment, the device could affect study outcomes.
Anticipates participating in any other drug or device study within the duration of the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Erie?

Yes, this clinical trial (NCT07419334) has an active research site in Erie, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Stargardt Disease Treatment Options in Erie, PA

If you're searching for stargardt disease treatment options in Erie, PA, this clinical trial (NCT07419334) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Erie research site is actively enrolling participants for this clinical trial. You'll receive care from experienced stargardt disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all stargardt disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Erie, PA

See all ankylosing spondylitis clinical trials recruiting in Erie — not just this study.

Browse Ankylosing Spondylitis Trials in Erie →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Erie?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Erie, PA